What is the Szent-Györgyi Prize?
The Szent-Györgyi Prize for Progress in Cancer Research was established in honor of NFCR’s co-founder, Albert Szent-Györgyi, M.D., Ph.D., who received the 1937 Nobel Prize for his study of vitamin C and cell respiration. The prize is a symbol of NFCR’s enduring commitment to uphold Dr. Szent-Györgyi’s vision of curing cancer through innovation and collaboration.
The annual prize honors scientists who have made an original discovery or breakthrough in scientific understanding that has had a lasting impact on the cancer field and a direct impact of saving people’s lives. In addition to winning the coveted award itself, prize recipients are given a $25,000 honorarium and attend a gala in their honor. The award serves to highlight the essential role basic research plays in understanding cancer.
Nominations for the Prize may be made by individuals from the research community, industry, government, or other organizations who are sufficiently familiar with the research accomplishments and contributions of the nominee. Self-nominations are not accepted. Candidates must have made an original discovery or breakthrough in scientific understanding that has led to better prevention, earlier diagnosis, or new treatments for patients with cancer.
The Szent-Györgyi Prize Selection Committee has been established to advise and consult with the National Foundation for Cancer Research on each year’s pool of Prize nominees.
The Prize Winner each year will serve as the selection chair of the Szent-Györgyi Prize Selection Committee for the following year.
2018 Award Recipient
Douglas R. Lowy, M.D., and John T. Schiller, Ph.D.
2018 Szent-Györgyi Prize for Progress in Cancer Research was awarded to Douglas R. Lowy, M.D., and John T. Schiller, Ph.D., for development of vaccines for human papilloma virus (HPV), which causes 99% of cervical cancer cases. Collaborators for over 30 years at the U.S. National Cancer Institute (NCI) in Bethesda, Lowy and Schiller developed the first Food and Drug Administration approved vaccines specifically targeting cancer.
“Doug Lowy and John Schiller have had monumental impact in the field of cancer sciences and could not be more deserving of this award,” stated Sujuan Ba, Ph.D., co-chair of the 2018 Prize selection committee and President of NFCR. “Many thousands of women’s lives have already been saved and exponentially more productive, disease-free years gained as a result of these two giants of oncology and virology.”
2019 Szent-Györgyi Prize Ceremony
Saturday, April 27th, 2019